Neuronetics Hopes Q4 Revenue Up 86% as Shares Rise

Neuronetics (NASDAQ:NEUR) reported a revised outlook for the fourth quarter, projecting revenue to increase 86% year-over-year to $48 million, up from $26.5 million previously. The revision follows positive feedback on its SPRAVKO therapy for treatment-resistant depression and reflects stronger-than-expected guidance from recent trials. The stock closed at $13.75, up 7.2% on the day, reflecting investor confidence in the revenue outlook and potential approval timelines.